GABAA receptor complex function in frontal cortex membranes from control and neurological patients.

Area of Science:

• Neuroscience
• Pharmacology
• Neurochemistry

Background:

• The GABAA receptor-benzodiazepine (BZ) recognition site is crucial for neuronal inhibition.
• Dysfunction of this complex is implicated in various neurological disorders.
• Assessing its integrity in postmortem human brain tissue is vital for understanding disease mechanisms.

Purpose of the Study:

• To evaluate the functional integrity of the GABAA receptor-benzodiazepine (BZ) recognition site-Cl- ionophore complex.
• To investigate [35S]TBPS binding in postmortem frontal cortex from control and neurodegenerative disease patients.
• To determine if BZ site agonists modulate [35S]TBPS binding in these tissues.

Main Methods:

• Utilized [35S]TBPS (t-butylbicyclophosphorothionate) binding assays.
• Prepared frontal cortex membranes from postmortem brain tissue of control, Alzheimer's, Parkinson's, and Huntington's chorea patients.
• Administered BZ site agonists (zolpidem, alpidem, flunitrazepam, clonazepam) to assess functional linkage.

Main Results:

• Specific [35S]TBPS binding was significantly reduced (78%) in Alzheimer's disease frontal cortex compared to controls.
• [35S]TBPS binding was comparable in control, Parkinson's, and Huntington's chorea brains.
• BZ agonists enhanced [35S]TBPS binding, confirming functional integrity of the GABAA receptor complex across all groups.

Conclusions:

• The GABAA receptor macromolecular complex is functionally intact in postmortem human brain tissue, even in neurodegenerative diseases.
• [35S]TBPS binding is a valuable tool for studying the GABAA receptor in postmortem human brain.
• Reduced [35S]TBPS binding in Alzheimer's disease suggests specific alterations at the receptor site.